Cite
RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma.
MLA
Chinnaiyan, Prakash, et al. “RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma.” International Journal of Radiation Oncology, Biology, Physics, vol. 86, no. 5, Aug. 2013, pp. 880–84. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2013.04.036.
APA
Chinnaiyan, P., Won, M., Wen, P. Y., Rojiani, A. M., Wendland, M., Dipetrillo, T. A., Corn, B. W., & Mehta, M. P. (2013). RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology, Biology, Physics, 86(5), 880–884. https://doi.org/10.1016/j.ijrobp.2013.04.036
Chicago
Chinnaiyan, Prakash, Minhee Won, Patrick Y. Wen, Amyn M. Rojiani, Merideth Wendland, Thomas A. Dipetrillo, Benjamin W. Corn, and Minesh P. Mehta. 2013. “RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma.” International Journal of Radiation Oncology, Biology, Physics 86 (5): 880–84. doi:10.1016/j.ijrobp.2013.04.036.